We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Paeonia lactiflora Pall. regulates the NF‐κB‐NLRP3 inflammasome pathway to alleviate cholestasis in rats.
- Authors
Ma, Xiao; Wen, Jian‐Xia; Gao, Si‐Jia; He, Xuan; Li, Peng‐Yan; Yang, Yu‐Xue; Wei, Shi‐zhang; Zhao, Yan‐Ling; Xiao, Xiao‐He
- Abstract
Objectives: Cholestasis is a critical risk factor for severe hepatic disease or cirrhosis. The anti‐inflammatory effect of Paeonia lactiflora Pall. (PLP), named Chishao in traditional Chinese medicine (TCM), on alpha‐naphthylisothiocyanate (ANIT)‐induced cholestasis model was tried to be elucidated in this research. Methods: Therapeutic effect indices on hepatic function, including ALT, AST, TBIL, DBIL, ALP, TBA and γ‐GT, were measured. To further investigate the protective mechanism of PLP, the mRNA and protein expression levels of NF‐κB‐NLRP3 inflammasome pathway were detected. Results: Our results showed that compared with the model group, PLP could significantly reduce the increased serum indices such as ALT, AST, TBIL, DBIL, ALP, TBA and γ‐GT induced by ANIT in a dose‐dependent way. Moreover, we found that PLP downregulated the mRNA expression levels including IKK, p65, NLRP3, caspase‐1 and IL‐1β, especially at the large dose. Furthermore, PLP also significantly inhibited NF‐κB‐NLRP3 inflammasome pathway by decreasing the protein levels of p65, p‐p65, p‐IKK, NLRP3, caspase‐1 and IL‐1β. Conclusions: The results indicated that PLP could ameliorate ANIT‐induced cholestasis in rats and the anti‐inflammatory effect of PLP might be related to regulating NF‐κB‐NLRP3 inflammasome pathway. This study will provide scientific evidence for PLP as a potential drug candidate for cholestasis.
- Subjects
CHOLESTASIS; HERBAL medicine; CHINESE medicine; APOPTOSIS; GENE expression
- Publication
Journal of Pharmacy & Pharmacology, 2018, Vol 70, Issue 12, p1675
- ISSN
0022-3573
- Publication type
Article
- DOI
10.1111/jphp.13008